Pharmacogenetic analysis of sorafenib in Egyptian patients with liver cancer
Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
This study is testing how genetic differences in Egyptian patients with liver cancer affect how well the drug sorafenib works and its safety.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Shibīn al Kawm, Menoufia) |
| Trial ID | NCT06527495 on ClinicalTrials.gov |
What this trial studies
This study investigates the pharmacogenetic factors influencing the effectiveness and safety of sorafenib in treating hepatocellular carcinoma (HCC) among Egyptian patients. By analyzing genetic polymorphisms in VEGFA and KDR, the study aims to tailor treatment to maximize therapeutic benefits while minimizing adverse effects. The trial includes patients aged 18 and older diagnosed with HCC who have not previously received systemic tyrosine kinase inhibitors. The findings could lead to more personalized treatment strategies for HCC patients.
Who should consider this trial
Good fit: Ideal candidates for this study are Egyptian patients aged 18 and older diagnosed with hepatocellular carcinoma who have not been treated with systemic TKIs.
Not a fit: Patients with liver tumors other than HCC, severe organ dysfunction, or those who cannot tolerate sorafenib will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the efficacy of sorafenib treatment for HCC patients and reduce the risk of side effects.
How similar studies have performed: While pharmacogenetic approaches in cancer treatment are gaining traction, this specific study's focus on sorafenib in the Egyptian population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age of all studied subjects ≥ 18 years old * All patients with hepatocellular carcinoma will be included in group I. * Patients not treated with systemic TKIs Exclusion Criteria: * Patients presented with liver tumors other than HCC. * Patients with Child-Pugh grade C for liver function. * Patients with other malignancies. * Patients with chronic inflammatory disorders. * Patients with severe organ dysfunction such as heart, lung, and kidney. * Patients who cannot tolerate or are allergic to sorafenib. * Patients with severe coagulation dysfunction were uncorrectable. * Age less than 18 years old.
Where this trial is running
Shibīn al Kawm, Menoufia
- Nli — Shibīn al Kawm, Menoufia, Egypt (Recruiting)
Study contacts
- Study coordinator: Mahmoud Nazih
- Email: Mahmoud.Nazih5698@pharm.aun.edu.eg
- Phone: 00201093859868
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.